A new study highlights both the promise and the limitations of gene editing, as a highly lethal form of avian influenza continues to spread around the world.
A trial of donanemab, an experimental drug, found it modestly slowed the worsening of memory and thinking and worked better in patients at earlier stages and those under 75.